

A N E X A 4 . 1

Nume Prenume: **BANCIU Manuela**

Gradul didactic: Profesor universitar

Instituția unde este titular: Universitatea Babeș-Bolyai

Facultatea: Biologie și Geologie

Departamentul: Biologie Moleculară și Biotehnologie

L I S T A lucrărilor științifice în domeniul disciplinelor din postul didactic

A. Teza de doctorat

Doctor in **Farmacie** al **Universității Utrecht** (Facultatea de Științe, Departamentul de Farmaceutică), **Olanda**; Data susținerii doctoratului -3 decembrie 2007 (atestat de echivalare nr. 26487/13.03.2008).

Titlul “Liposomal Targeting of Glucocorticoids to Inhibit Tumor Angiogenesis”

(<https://dspace.library.uu.nl/bitstream/handle/1874/24452/index.htm%3Bjsessionid=41CB336F51EBD687617B2EBF4764A9E2?sequence=16>)

Conducători științifici: Prof. Dr. Gert Storm; dr. Raymond Schiffelers.

B. Cărți și capitole în cărți publicate în ultimii 10 ani

-

C. Lucrări indexate ISI/BDI publicate în ultimii 10 ani

În calitate de autor principal

1. Alupei MC, Licarete E, Cristian FB, **Banciu M.** (2014). Cytotoxicity of lipophilic statins depends on their combined actions on HIF-1 α expression and redox status in B16.F10 murine melanoma cells. *Anticancer Drugs*. 25(4): 393-405. <https://doi.org/10.1097/CAD.0000000000000065> FI 2014= 1.784.
2. Pap PL, Sesarman A, Vágási CI, Buehler DM, Pătraș L, Versteegh MA, **Banciu M.** (2014). No evidence for parasitism-linked changes in immune function or oxidative physiology over the annual cycle of an avian species. *Physiol Biochem Zool*. 87(5): 729-39 <https://doi.org/10.1086/681243> FI 2014= 2.398.
3. Alupei MC, Licarete E, Patras L, **Banciu M** (2015). Liposomal simvastatin inhibits tumor growth via targeting tumor-associated macrophages-mediated oxidative stress. *Cancer Lett*. 356 (2):946-952. <https://doi.org/10.1016/j.canlet.2014.11.010> FI 2015= 5.992.
4. Porfire A., Tomuta I., Muntean D., Luca L., Licarete E., Alupei M.C., Achim M., Vlase L., **Banciu M.** (2015). Optimizing long-circulating liposomes for delivery of simvastatin to C26 colon carcinoma cells. *J Liposome Res*. 25(4):261-9. <https://doi.org/10.3109/08982104.2014.987787> FI 2015= 1.797.

5. Licarete E, Sesarman A, **Banciu M.** (2015) Exploitation of pleiotropic actions of statins by using tumour-targeted delivery systems. *J Microencapsul.* 32(7):619-31.
<https://doi.org/10.3109/02652048.2015.1073383> FI 2015= 1.631.
6. Patras L, Sesarman A, Licarete E, Luca L, Alupei MC, Rakosy-Tican E, **Banciu M.** (2016) Dual role of macrophages in the response of C26 colon carcinoma cells to 5-fluorouracil administration. *Oncol Lett.* 12(2):1183-1191. <https://doi.org/10.3892/ol.2016.4708> FI 2016= 1.390.
7. Licarete E, Sesarman A, Rauca VF, Luput L, Patras L, **Banciu M.**(2017). HIF-1 α acts as a molecular target for simvastatin cytotoxicity in B16.F10 melanoma cells cultured under chemically induced hypoxia. *Oncol Lett.* 13(5): 3942-3950. <https://doi.org/10.3892/ol.2017.5928> FI 2017= 1.664.
8. Achim M, Tomuta I, Muntean D, Porfire A, Tefas LR, Patras L, Licarete E, Alupei MC, Vlase L, **Banciu M.** (2017) Optimization and in vitro evaluation of 5-fluorouracil - loaded long - circulating liposomes, FARMACIA 65 (1): 82-91. <https://farmaciajournal.com/issue-articles/optimization-and-in-vitro-evaluation-of-5-fluorouracil-loaded-long-circulating-liposomes/> FI 2017= 1.507.
9. Patras L, Sylvester B, Luput L, Sesarman A, Licarete E, Porfire A, Muntean D, Drotar DM, Rusu AD, Nagy AL, Catoi C, Tomuta I, Vlase L, **Banciu M**, Achim M (2017) Liposomal prednisolone phosphate potentiates the antitumor activity of liposomal 5-fluorouracil in C26 murine colon carcinoma in vivo *Cancer Biol Ther* 18(8): 616-626 (autor corespondent). <https://doi.org/10.1080/15384047.2017.1345392> FI 2017= 3.373.
10. Luput L, Licarete E, Sesarman A, Patras L, Alupei MC, **Banciu M.** (2017). Tumor-associated macrophages favor C26 murine colon carcinoma cell proliferation in an oxidative stress-dependent manner. *Oncol Rep* 37(4): 2472-2480. <https://doi.org/10.3892/or.2017.5466> FI 2019= 3. 417.
11. Sesarman A, Tefas L, Sylvester B, Licarete E, Rauca V, Luput L, Patras L, **Banciu M**, Porfire A (2018) Anti-angiogenic and anti-inflammatory effects of long-circulating liposomes co-encapsulating curcumin and doxorubicin on C26 murine colon cancer cells *Pharmacol Rep* 70(2): 331-339 (autor corespondent) <https://doi.org/10.1016/j.pharep.2017.10.004> FI 2018= 2.761.
12. Luput L, Licarete E, Drotar DM, Nagy AL, Sesarman A, Patras L, Rauca VF, Porfire A, Muntean D, Achim M, Tomuta I, Vlase L, Catoi C, Dragos N, **Banciu M** (2018) In Vivo Double Targeting of C26 Colon Carcinoma Cells and Microenvironmental Protumor Processes Using Liposomal Simvastatin *J Cancer* 9 (2): 440-449. <https://doi.org/10.7150/jca.21560> FI 2018=3.182.
13. Rauca VF, Licarete E, Luput L, Sesarman A, Patras L, Bulzu P, Rakosy-Tican E, **Banciu M** (2018) Combination therapy of simvastatin and 5, 6-dimethylxanthenone-4-acetic acid synergistically suppresses the aggressiveness of B16.F10 melanoma cells, *PLoS ONE* 13(8):e0202827. <https://doi.org/10.1371/journal.pone.0202827> FI 2018=2.776.
14. Sesarman A, Tefas L, Sylvester B, Licarete E, Rauca V, Luput L, Patras L, Porav S, **Banciu M**, Porfire A. (2019) Co-delivery of curcumin and doxorubicin in PEGylated liposomes favored the antineoplastic C26 murine colon carcinoma microenvironment. *Drug Deliv Transl Res.* 9 (1): 260-272 (autor corespondent) <https://doi.org/10.1007/s13346-018-00598-8> FI 2019 = 2.664.
15. Patras L, **Banciu M** (2019) Intercellular Crosstalk Via Extracellular Vesicles in Tumor Milieu as Emerging Therapies for Cancer Progression. *Curr Pharm Des.* 25(17):1980-2006
<https://doi.org/10.2174/1381612825666190701143845> FI 2019 = 2.208.

16. Licarete E, Rauca VF, Luput L, Patras L, Sesarman A, **Banciu M.** (2019) The prednisolone phosphate-induced suppression of the angiogenic function of tumor-associated macrophages enhances the antitumor effects of doxorubicin on B16.F10 murine melanoma cells in vitro. *Oncol Rep.* 42(6):2694-2705 <https://doi.org/10.3892/or.2019.7346> FI 2019= 3.417.
17. Luput L, Sesarman A, Porfire A, Achim M, Muntean D, Casian T, Patras L, Rauca VF, Drotar DM, Stejerean I, Tomuta I, Vlase L, Dragos N, Toma VA, Licarete E, **Banciu M.** (2020) Liposomal simvastatin sensitizes C26 murine colon carcinoma to the antitumor effects of liposomal 5-fluorouracil in vivo. *Cancer Sci.* doi: <https://doi.org/10.1111/cas.14312> FI 2020=6.716.
18. Patras L, Fens MHAM, Vader P, Barendrecht A, Sesarman A, **Banciu M**, Schiffelers R.(2020) Normoxic Tumour Extracellular Vesicles Modulate the Response of Hypoxic Cancer and Stromal Cells to Doxorubicin In Vitro *Int J Mol Sci.*;21(17):5951. (autor corespondent) <https://doi.org/10.3390/ijms21175951> FI 2020=5.924.
19. Licarete E, Rauca VF, Luput L, Drotar D, Stejerean I, Patras L, Dume B, Toma VA, Porfire A, Gherman C, Sesarman A, **Banciu M.** (2020) Overcoming Intrinsic Doxorubicin Resistance in Melanoma by Anti-Angiogenic and Anti-Metastatic Effects of Liposomal Prednisolone Phosphate on Tumor Microenvironment. *Int J Mol Sci.* 21(8):2968. <https://doi.org/10.3390/ijms21082968> FI 2020=5.924.
20. Rauca VF, Patras L, Luput L, Licarete E, Toma VA, Porfire A, Mot AC, Rakosy-Tican E, Sesarman A, **Banciu M.** (2021) Remodeling tumor microenvironment by liposomal codelivery of DMXAA and simvastatin inhibits malignant melanoma progression. *Sci Rep.* 11(1):22102. <https://doi.org/10.1038/s41598-021-01284-5> FI 2021=4.997.
21. Patras L, Ionescu AE, Munteanu C, Hajdu R, Kosa A, Porfire A, Licarete E, Rauca VF, Sesarman A, Luput L, Bulzu P, Chiroi P, Tranca RA, Meszaros MS, Negrea G, Barbu-Tudoran L, Potara M, Szedlacsek S, **Banciu M.** (2022) Trojan horse treatment based on PEG-coated extracellular vesicles to deliver doxorubicin to melanoma *in vitro* and *in vivo*. *Cancer Biol Ther.* 23(1):1-16. <https://doi.org/10.1080/15384047.2021.2003656> FI 2022=3.6.
22. Ranamalla SR, Porfire AS, Tomuță I, **Banciu M.** (2022) An Overview of the Supramolecular Systems for Gene and Drug Delivery in Tissue Regeneration. *Pharmaceutics.* Aug 18;14(8):1733. <https://doi.org/10.3390/pharmaceutics14081733> FI 2022=5.4.
23. Negrea G, Rauca VF, Meszaros MS, Patras L, Luput L, Licarete E, Toma VA, Porfire A, Muntean D, Sesarman A, **Banciu M.** (2022) Active Tumor-Targeting Nano-formulations Containing Simvastatin and Doxorubicin Inhibit Melanoma Growth and Angiogenesis. *Front Pharmacol.* 13:870347. <https://doi.org/10.3389/fphar.2022.870347> FI 2022=5.6.
24. Sesarman A, Luput L, Rauca VF, Patras L, Licarete E, Meszaros MS, Dume BR, Negrea G, Toma VA, Muntean D, Porfire A, Banciu M. (2024) Targeting of M2 macrophages with IL-13-functionalized liposomal prednisolone inhibits melanoma angiogenesis in vivo. *J Liposome Res.* 2024 20:1-12 <https://doi.org/10.1080/08982104.2024.2315452> FI 2023=3.6
25. Dume B, Licarete E, Banciu M (2024) Advancing Cancer Treatments: The role of oligonucleotides-based therapies in driving progress, *Molecular Therapy: Nucleic Acid* (2024), 35(3) : 102256 <https://doi.org/10.1016/j.omtn.2024.102256> FI 2023=6.5.

În calitate de coautor

26. Baldea I, Olteanu DE, Bolfa P, Ion RM, Decea N, Cenariu M, **Banciu M**, Sesarman AV, Filip AG.(2015) Efficiency of photodynamic therapy on WM35 melanoma with synthetic porphyrins: Role of chemical structure, intracellular targeting and antioxidant defense. *J Photochem Photobiol B.* 151:142-52 <https://doi.org/10.1016/j.jphotobiol.2015.07.019> FI 2015= 3.035.
27. Simon T, Potara M, Gabudean AM, Licarete E, **Banciu M**, Astilean S. (2015) Designing Theranostic Agents Based on Pluronic Stabilized Gold Nanoaggregates Loaded with Methylene Blue for Multimodal Cell Imaging and Enhanced Photodynamic Therapy. *ACS Appl Mater Interfaces.* 7(30):16191-201. <https://doi.org/10.1021/acsmami.5b04734> FI 2015= 7.145.
28. Potara M, Bawaskar M, Simon T, Gaikwad S, Licarete E, Ingle A, **Banciu M**, Vulpoi A, Astilean S, Rai M. (2015) Biosynthesized silver nanoparticles performing as biogenic SERS-nanotags for investigation of C26 colon carcinoma cells. *Colloids Surf B Biointerfaces.* 133:296-303.<https://doi.org/10.1016/j.colsurfb.2015.06.024> FI 2015= 3.902.
29. Pap PL, Pătraș L, Osváth G, Buehler DM, Versteegh MA, Sesarman A, **Banciu M**, Vágási CI. (2015) Seasonal Patterns and Relationships among Coccidian Infestations, Measures of Oxidative Physiology, and Immune Function in Free-Living House Sparrows over an Annual Cycle. *Physiol Biochem Zool.* 88(4):395-405. <https://doi.org/10.1086/681243> FI 2015=2.007.
30. Tefas LR, Sylvester B, Tomuta I, Sesarman A, Licarete E, **Banciu M**, Porfire A.(2017) Development of antiproliferative long-circulating liposomes co-encapsulating doxorubicin and curcumin, through the use of a quality-by-design approach. *Drug Des Devel Ther.* 11:1605-1621 <https://doi.org/10.2147/DDDT.S129008> FI 2017=2.935.
31. Sylvester B, Porfire A, Muntean DM, Vlase L, Lupuț L, Licarete E, Sesarman A, Alupei MC, **Banciu M**, Achim M, Tomuță I.(2018) Optimization of prednisolone-loaded long-circulating liposomes via application of Quality by Design (QbD) approach. *J Liposome Res* 28(1): 49-61. <https://doi.org/10.1080/08982104.2016.1254242> FI 2018 = 2.507.
32. Popa R, Licarete E, **Banciu M**, Sivestru A (2018) Organoselenium compounds containing pyrazole or phenylthiazole groups. Synthesis, structure, tin(IV) complexes and antiproliferative activity. *Appl. Organomet Chem* 32(4): e4252.<https://doi.org/10.1002/aoc.4252> FI 2018 = 3.259.
33. Rauca VF, Vlase L, Casian T, Sesarman A, Gheldiu AM, Mocan A, **Banciu M**, Toiu A (2019) Biologically Active Ajuga Species Extracts Modulate Supportive Processes for Cancer Cell Development, *Front. Pharmacol.*, 10:334. doi: 10.3389/fphar.2019.00334 eCollection 2019. <https://doi.org/10.3389/fphar.2019.00334> FI 2018= 3.845.
34. Sesarman A, Muntean D, Abrudan B, Tefas L, Sylvester B, Licarete E, Rauca V, Luput L, Patras L, **Banciu M**, Vlase L, Porfire A. (2021). Improved pharmacokinetics and reduced side effects of doxorubicin therapy by liposomal co-encapsulation with curcumin *J Liposome Res*;31(1):1-10. <https://doi.org/10.1080/08982104.2019.1682604> FI 2019 = 2.455.
35. Vieriu, SM, Somesan, AA, Silvestru, C, Licarete, E, **Banciu, M**, Varga, RA. (2021). Synthesis, structural characterization and in vitro antiproliferative effects of novel organotin(iv) compounds with nicotinate and isonicotinate moieties on carcinoma cells, *New J Chem*; 45 (2): 1020-1028. <https://doi.org/10.1039/d0nj05069e> FI 2021=3.925.
36. Popa R, David M, Licarete E, **Banciu M**, Sivestru A (2022). On the coordination behaviour of diorganoselenium ligands based on amino and azole functionalities: silver(i) complexes with relevance for biological applications, *New J Chem*; 46(48): 23019-23029.<https://doi.org/10.1039/D2NJ04812D> FI 2022=3.3.

37. Suarasan S, Campu A, Vulpoi A, **Banciu M**, Astilean S.(2022) Assessing the Efficiency of Triangular Gold Nanoparticles as NIR Photothermal Agents In Vitro and Melanoma Tumor Model. *Int J Mol Sci.* 23(22):13724. <https://doi.org/10.3390/ijms232213724> FI 2022=5.6.
38. Tefas LR, Toma I, Sesarman A, **Banciu M**, Jurj A, Berindan-Neagoe I, Rus L, Stiufluc R, Tomuta I. (2022) Co-delivery of gemcitabine and salinomycin in PEGylated liposomes for enhanced anticancer efficacy against colorectal cancer. *J Liposome Res.* 15:1-17. <https://doi.org/10.1080/08982104.2022.2153139> FI 2022=4.4.
38. Corjuc L, Pop A, Licarete E, **Banciu M**, Silvestru A.(2024) Silver(I) complexes with diorganochalcogen ligands of type(2-MeC₆H₄CH₂)₂E (E = S, Se). Synthesis, structure and antiproliferative activity. *Inorganica Chim. Acta.* 2024 Volume 565, 24 May 2024, 121972 <https://doi.org/10.1016/j.ica.2024.121972> FI 2023=2.7.
39. Tiadar ED, Chiriac CM, Pošćić F, Văcar CL, Balázs ZR, Coman C, Weindorf DC, **Banciu M**, Krämer U & Podar D. (2024) Plant colonizers of a mercury contaminated site: trace metals and associated rhizosphere bacteria. *Plant Soil* <https://doi.org/10.1007/s11104-024-06552-7> FI 2023=3.9.
40. Ranamalla, SR, Tavakoli, S, Porfire, AS, Tefas, LR, **Banciu, M**, Tomuta, I, Varghese, OP (2024) CARBOHYDRATE POLYMERS Volume: 339 Article Number: 122251 <https://doi.org/10.1016/j.carbpol.2024.122251> FI 2023=10.7.

D. Publicații in extenso apărute în volume ale principalelor conferințe internaționale de specialitate - Selecție cu maximum 20 lucrări în volume de conferințe în ultimii 10 ani.

-

E. Alte lucrări și contribuții științifice

(lucrări științifice publicate în jurnale indexate în BDI, în calitate de autor principal sau coautor) **în ultimii 10 ani**

41. Rusu AD, Pătraș L, **Banciu M.** (2015) Overview on Nanoparticulate Formulations for 5-fluorouracil Delivery in Colorectal Cancer Treatment. *Studia Univ Babes-Bolyai, Biologia* 60 (2): 89-96.http://studia.ubbcluj.ro/download/pdf/Biologia_pdf/2015_2/08.pdf
42. Emilia A, Sabău F, Vădan A, Marinescu M, Licărete E, Roșioru C, Stoica AD, Dobre C, **Banciu M** (2024). Assessment of circulating biomarkers in a rat model of doxorubicin-induced cardiotoxicity. *Studia Universitatis Babeș-Bolyai, Biologia*, 2024, Vol 69, Issue 2, p7 <https://studiobiologia.reviste.ubbcluj.ro/index.php/studiabio/article/view/214>

F. Brevete obținute în întreaga activitate

-

Data:

6/05/2025

Semnătura:

